Table 3. Univariate crude rates and hazard ratio (Cox) for biomarkers and luminal phenotype.

	IBTR (n=24)			LRR (n=35)			DDFS (n=47)			BCSS (n=37)
	CR	HR (95% CI)	P	CR	HR (95% CI)	P	CR	HR (95% CI)	P	CR	HR (95% CI)	P
Ki67 high	12/129	3.126 (1.390–7.029)	0.0008	19/129	3.759 (1.923–7.340)	0.0001	24/129	3.436 (1.926–6.130)	<0.0001	22/129	4.948 (2.530–9.674)	<0.0001
p53+	3/57	1.067 (0.315–3.629)	0.916	5/57	1.290 (0.497–3.350)	0.601	11/57	2.566 (1.303–5.056)	0.006	11/57	3.523 (1.731–7.168)	0.0005
LA	15/394	0.433 (0.186–1.005)	0.051	20/394	0.333 (0.169–0.655)	0.002	30/394	0.446 (0.246–0.810)	0.008	23/394	0.414 (0.213–0.816)	0.009
LB	2/23	2.132 (0.500–9.098)	0.307	2/23	1.365 (0.327–5.697)	0.669	2/23	0.963 (0.233–3.971)	0.958	2/23	1.258 (0.302–5.234)	0.753
Modified LA	9/321	0.314 (0.136–0.726)	0.007	11/321	0.233 (0.113–0.478)	<0.0001	16/321	0.263 (0.144–0.481)	0.0001	11/321	0.218 (0.108–0.441)	<0.0001
Modified LB	8/96	2.217 (0.0.945–5.200)	0.07	11/96	2.036 (0.995–4.167)	0.052	16/96	2.351 (1.285–4.300)	0.005	14/96	2.733 (1.406–5.314)	0.003

Abbreviations: CI=confidence interval; CR=crude rate; DMFS=distant metastasis-free survival; ER+ =oestrogen receptor positive; HR=hazard ratio; IBTR=ipsilateral breast tumour recurrence; LA=luminal A; LB=luminal B; LRR=locoregional recurrence; PR+ =progesterone receptor positive.

LA: ER+ and/or PR+ and HER2− LB: B ER+ and/or PR+ and HER2+ modified LA: ER+ and/or PR+, Ki-67 low, p53−, HER2− modified LB: ER+ and/or PR+ and/or Ki-67 high and/or p53+ and/or HER2+.

Bold typescript indicates statistical significance.